Snapshot from Aug 06, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Lundbeck completes DEEp OCEAN enrollment
Business clinical trial milestone

Lundbeck completes DEEp OCEAN enrollment

Analysis based on 8 articles · First reported Jul 20, 2026 · Last updated Jul 20, 2026

Sentiment
40
Attention
3
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The milestone de-risks Lundbeck's bexicaserin program, potentially boosting investor confidence. Positive results could open a large unmet need market in DEEs, with no approved therapies across all subtypes.

biotechnology pharmaceuticals
Event Summary

Lundbeck announced that the last patient has been randomized in the DEEp OCEAN Phase III trial evaluating bexicaserin for seizures associated with developmental and epileptic encephalopathies (DEEs). The global trial enrolled over 350 participants aged 2-65 years across diverse DEE syndromes. Headline results are expected by end of Q4 2026 or Q1 2027. Bexicaserin has received Breakthrough Therapy Designation from the U.S. FDA and China for DEEs. Recruitment for the companion DEEp SEA trial in Dravet syndrome is progressing well.

Key Actions
80 Lundbeck randomized last patient
60 United States — Food and Drug Administration granted Breakthrough Therapy Lundbeck
60 China granted Breakthrough Therapy Lundbeck
Entities Involved
priv
Lundbeck
Lundbeck achieved a key enrollment milestone for its lead pipeline asset bexicaserin, advancing toward potential approval in DEEs.
Importance 100.0 Sentiment 40.0
govactor
United States — Food and Drug Administration
Granted Breakthrough Therapy Designation for bexicaserin in DEEs, facilitating development.
Importance 40.0 Sentiment 0.0
cnt
China
Granted Breakthrough Therapy Designation for bexicaserin, indicating regulatory support in a key market.
Importance 30.0 Sentiment 0.0
per
Ingrid Scheffer
Lead investigator of the DEEp OCEAN trial, providing scientific credibility.
Importance 30.0 Sentiment 0.0
cnt
United States
Regulatory environment in the U.S. supports bexicaserin development via FDA designation.
Importance 20.0 Sentiment 0.0
per
Johan Luthman
Lundbeck's R&D head, announced the milestone and expressed confidence in the program.
Importance 20.0 Sentiment 0.0
cnt
Denmark
Home country of Lundbeck; event may have minor positive local economic impact.
Importance 10.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ China
United States — Food and Drug Administration related ↔ United States
China strategic rivals ↔ United States China views the United States as a strategic rival, characterized by ongoing trade disputes, technological competition,
China related ↔ Denmark
United States related ↔ Denmark
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.